Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-iga1 antibody

A technology of antibody and antibody fragment, which is applied in the direction of antibody, recombinant DNA technology, anti-receptor/cell surface antigen/cell surface determinant immunoglobulin, etc. It can solve the problem of accelerating the disappearance of mouse antibodies and reducing the therapeutic effect of mouse antibodies, etc. question

Inactive Publication Date: 2012-10-03
KYOWA HAKKO KIRIN CO LTD
View PDF29 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It is known that HAMA reacts with the administered mouse antibody to cause side effects (Non-Patent Documents 13-16), or accelerates the disappearance of the mouse antibody in the body (Non-Patent Documents 17-19), reducing the therapeutic effect of the mouse antibody ( Non-Patent Literature 20, 21)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-iga1 antibody
  • Anti-iga1 antibody
  • Anti-iga1 antibody

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0222] (1) Antigen preparation

[0223] An expression vector containing a cDNA encoding a full-length or partial-length IgA1 heavy chain is introduced into an enzyme that adds Gal to GalNAc bound to Ser / Thr on a polypeptide during synthesis of an O-linked sugar chain by the method described below. , proteins related to the activity of the enzyme or proteins related to the transport of UDP-galactose, etc. have been reduced or deleted in yeast, insect cells, animal cells, etc., thereby obtaining sugar chain-deficient IgA1 as an antigen protein or cells expressing sugar chain-deficient IgA1. In addition, a method of preparing an antigen by purifying sugar chain-deficient IgA1 from various human-derived cultured cells, human tissues, etc. expressing sugar chain-deficient IgA1 in large quantities on the cell membrane or in a culture medium, or preparing A synthetic peptide having a partial sequence of sugar chain-deficient IgA1 was used as an antigen. In addition, sugar chain-def...

Embodiment 1

[0360] Production of CHO Cell Line Highly Expressing Sugar Chain-deficient IgA1 on Cell Membrane

[0361] (1) Construction of membrane-type IgA expression plasmid pKAN932B8PVHmIgA

[0362] The vector pKAN932B8PVHmIgA for expressing membrane immunoglobulin A on the cell membrane was prepared in the following procedure. This plasmid is a plasmid vector for expressing a protein obtained by linking the heavy chain Fab portion of anti-CD20 antibody 2B8P to the constant region of membrane immunoglobulin described in Patent WO03 / 085107.

[0363] 1. Production of pCR2B8PVH

[0364] Using the plasmid vector pKANTEX932B8P described in Patent WO03 / 085107 as a template, the gene fragment including the heavy chain variable region of the anti-CD20 antibody 2B8P was amplified by the PCR reaction shown below. 1 ng of pKANTEX932B8P, 1 micromol / liter RitNotNheIfw (sequence number 4), 1 micromol / liter RitNotNheIrv (sequence number 5) and 2.5 units KOD polymerase (manufactured by Toy...

Embodiment 2

[0376] Preparation of sugar chain-deficient IgA1-Fc fusion protein

[0377] In order to obtain soluble mIgA1 protein, an Fc fusion protein mIgA1-Fc in which the extracellular region of mIgA1 is linked to human IgG4 Fc was designed. Specifically, a gene fragment in which a part of the extracellular region of mIgA1 was linked to human IgG4 Fc was prepared by the PCR method and inserted into pKAN932B8PVHmIgA obtained in Example 1 to prepare the Fc-fused mIgA1 expression vector pKANTEX-mIgA1- Fc. This expression vector was introduced into CHO / DG44 cell line and Lec8 cell line, and 500 μg / mL of G418 was added to the medium to screen the gene-transferred cells. The selected gene-introduced cells were cultured in serum-free medium Excell-302 (SAFC) for one week to obtain a culture supernatant containing mIgA1-Fc. Using a Mabselect (GE Healthcare) column, purification was performed from about 1 liter of the culture supernatant according to the attached instructions to obtain abo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Particle sizeaaaaaaaaaa
Login to View More

Abstract

Provided is a monoclonal antibody, effective in diagnosing IgA nephropathy, that specifically recognizes and bonds to the hinge region of a polypeptide coded for by the immunoglobulin A1 heavy chain gene, which contains a serine / threonine-linked sugar chain with no galactose bound thereto. Also provided are a fragment of said antibody, a diagnostic agent using the provided antibody or antibody fragment, and a therapeutic agent containing the provided antibody or antibody fragment as an active ingredient.

Description

technical field [0001] The present invention relates to a monoclonal antibody or the antibody fragment, which specifically recognizes and binds to the hinge region of a polypeptide encoded by the heavy chain gene of immunoglobulin A1, said hinge region comprising a galactose-unbound serine threonine linkage type sugar chain; and a hybridoma producing the antibody, a DNA encoding the antibody, a vector containing the DNA, a transformant obtained by transforming the vector, an antibody or an antibody fragment using the hybridoma or transformant A production method, a diagnostic agent using the antibody or antibody fragment, and a therapeutic agent containing the antibody or antibody fragment as an active ingredient. Background technique [0002] In recent years, examples have been reported that, accompanying the onset and progression of various diseases, the structure of sugar chains attached to proteins expressed by cells associated with the diseases and conditions changes. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N15/09A61K39/395A61P13/12A61P37/02C07K16/42C07K16/46C12N1/15C12N1/19C12N1/21C12N5/10C12N15/02C12P21/08G01N33/53
CPCC07K16/4283G01N2800/34C07K2317/34C07K2317/92A61P13/12A61P37/02A61K38/17A61K38/20A61K39/395A61K48/00C07K14/435C07K14/54C07K16/18C07K16/22C07K16/24C07K16/28C07K16/42
Inventor 金子悦士佐佐木由香森胜弘神田丰佐藤光男
Owner KYOWA HAKKO KIRIN CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com